We currently focus on gastrointestinal, metabolic and other specialty diseases where we believe that the present standard of care is inadequate and where we believe that we have the resources to advance our peptide-based product candidates into the later stages of clinical development, including registration and, potentially, commercialization, while opportunistically considering partnership relationships that may arise. In addition, we are looking to focus our efforts on drug candidates that may qualify for orphan / rare disease status
Peptides have proven to be effective drugs in a number of different diseases, with a significant untapped potential across many therapy areas. We are committed to deliver innovation and life-changing impact for people suffering from some of these specialty and rare diseases.
Gastrointestinal (GI) diseases – read more